4.8 Article

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Cardiac & Cardiovascular Systems

Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial

Jasper Tromp et al.

Summary: The EMPULSE trial aims to assess the clinical benefits and safety of the SGLT2 inhibitor empagliflozin compared to placebo in patients hospitalized for AHF. Approximately 500 patients across North America, Europe, and Asia will be randomized to receive either empagliflozin or placebo, with the primary outcome being clinical benefit at 90 days. Secondary outcomes include safety assessments and changes in symptom scores and natriuretic peptides.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Medicine, General & Internal

Effects of Serelaxin in Patients with Acute Heart Failure

Marco Metra et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Medicine, General & Internal

Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure

Eric J. Velazquez et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Pharmacology & Pharmacy

The stratified win ratio

Gaohong Dong et al.

JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2018)

Article Medicine, General & Internal

Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure

M. Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Review Cardiac & Cardiovascular Systems

The vulnerable phase after hospitalization for heart failure

Stephen J. Greene et al.

NATURE REVIEWS CARDIOLOGY (2015)

Article Medicine, General & Internal

Rolofylline, an Adenosine A(sub 1)-Receptor Antagonist, in Acute Heart Failure.

Barry M. Massie et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Medicine, General & Internal

Effects of oral tolvaptan in patients hospitalized for worsening heart failure - The EVEREST outcome trial

Marvin A. Konstam et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)